EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma
Open Access
- 14 July 2025
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-12
Abstract
T-cell lymphoma (TCL) is a rare subtype of non-Hodgkin lymphoma (NHL) that is associated with a poor prognosis. Although HDAC inhibitors have been approved for TCL treatment for several years, their expected therapeutic efficacy remains unmet in some patients. In this study, we discovered that TCL tumor cells develop resistance to HDAC inhibitor treatment by upregulating the methylation of lysine 27 on histone H3 (H3K27me3) levels. Furthermore, we confirmed the pharmacological efficacy of the EZH2 inhibitor SHR2554 and demonstrated a synergistic effect when combined with the HDAC inhibitor Chidamide through commercial TCL cell lines, in vivo cell-derived xenograft, and patient-derived xenograft cancer models. We inferred that STAT1 was the key driver of the synergistic effect using RNA-seq and ChIP-seq analysis. Our findings provide sufficient preclinical evidence in support of a potential combination therapy strategy for TCL patients.Keywords
This publication has 51 references indexed in Scilit:
- Recent histone deacetylase inhibitors in cancer therapyCancer, 2023
- Targeting histone deacetylases for cancer therapy: Trends and challengesActa Pharmaceutica Sinica B, 2023
- Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphomaHematological Oncology, 2022
- EBF3 reactivation by inhibiting the EGR1/EZH2/HDAC9 complex promotes metastasis via transcriptionally enhancing vimentin in nasopharyngeal carcinomaCancer Letters, 2022
- Mechanism of berberine in treating Helicobacter pylori induced chronic atrophic gastritis through IRF8-IFN-γ signaling axis suppressingLife Sciences, 2020
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid TumorsCell, 2018
- Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian CancerCell Reports, 2018
- Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activityEuropean Journal of Cancer, 2017
- EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastomaCancer Letters, 2015
- EZH2-Mediated Inactivation of IFN-γ-JAK-STAT1 Signaling Is an Effective Therapeutic Target in MYC-Driven Prostate CancerCell Reports, 2014